[go: up one dir, main page]

NO992692L - Nefadozon doseringsform - Google Patents

Nefadozon doseringsform

Info

Publication number
NO992692L
NO992692L NO992692A NO992692A NO992692L NO 992692 L NO992692 L NO 992692L NO 992692 A NO992692 A NO 992692A NO 992692 A NO992692 A NO 992692A NO 992692 L NO992692 L NO 992692L
Authority
NO
Norway
Prior art keywords
nefadozone
dosage form
dosage
nefadozone dosage
Prior art date
Application number
NO992692A
Other languages
English (en)
Other versions
NO992692D0 (no
Inventor
Andrew B Dennis
Peter Timmins
Alison C Hodson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO992692D0 publication Critical patent/NO992692D0/no
Publication of NO992692L publication Critical patent/NO992692L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO992692A 1998-06-05 1999-06-03 Nefadozon doseringsform NO992692L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8821198P 1998-06-05 1998-06-05

Publications (2)

Publication Number Publication Date
NO992692D0 NO992692D0 (no) 1999-06-03
NO992692L true NO992692L (no) 1999-12-06

Family

ID=22210038

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992692A NO992692L (no) 1998-06-05 1999-06-03 Nefadozon doseringsform

Country Status (20)

Country Link
US (1) US6143325A (no)
EP (1) EP0966966A3 (no)
JP (1) JP2000007567A (no)
KR (1) KR20000005930A (no)
CN (1) CN1238181A (no)
AR (1) AR018862A1 (no)
AU (1) AU3319999A (no)
BR (1) BR9901782A (no)
CA (1) CA2273546A1 (no)
CO (1) CO5060477A1 (no)
HU (1) HUP9901830A2 (no)
ID (1) ID23458A (no)
IL (1) IL130022A0 (no)
NO (1) NO992692L (no)
NZ (1) NZ336001A (no)
PE (1) PE20000544A1 (no)
PL (1) PL333524A1 (no)
SG (1) SG77244A1 (no)
UY (1) UY25544A1 (no)
ZA (1) ZA993345B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
EP1428535A1 (en) * 1998-11-02 2004-06-16 ALZA Corporation Controlled delivery of antidepressants
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
KR20070040421A (ko) * 1998-11-02 2007-04-16 알자 코포레이션 항우울제의 제어된 전달
AU2002306616A1 (en) * 2001-03-02 2002-09-19 Sepracor Inc. Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004033A1 (en) 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
DE60219478T2 (de) 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
WO2003099265A2 (de) * 2002-05-24 2003-12-04 Coester Carl-Fr Pharmazeutische wirkstoffkombination sowie deren verwendung
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
AU2003264002B2 (en) 2003-08-08 2010-09-02 Valeant International Bermuda Modified-release tablet of bupropion hydrochloride
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
JP2011140510A (ja) * 2011-03-17 2011-07-21 Biovail Lab Inc 塩酸ブプロピオンの放出調節錠剤
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
JP6184903B2 (ja) * 2014-06-04 2017-08-23 ヴァレアント インターナショナル バミューダＶａｌｅａｎｔ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｂｅｒｍｕｄａ 塩酸ブプロピオン放出調節錠剤
JP6078514B2 (ja) * 2014-10-30 2017-02-08 コリア ユナイテッド ファーム，インク 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
EP0859597B1 (en) * 1995-09-29 2003-04-09 LAM Pharmaceutical Corporation Sustained release delivery system and long acting narcotic analgesics and antagonists
WO1997047285A1 (en) * 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form

Also Published As

Publication number Publication date
EP0966966A2 (en) 1999-12-29
CO5060477A1 (es) 2001-07-30
UY25544A1 (es) 2001-08-27
CA2273546A1 (en) 1999-10-10
BR9901782A (pt) 2000-05-09
AU3319999A (en) 1999-12-16
CN1238181A (zh) 1999-12-15
NZ336001A (en) 2000-09-29
PL333524A1 (en) 1999-12-06
SG77244A1 (en) 2000-12-19
ZA993345B (en) 2000-08-22
ID23458A (id) 2000-04-27
AR018862A1 (es) 2001-12-12
HU9901830D0 (en) 1999-07-28
KR20000005930A (ko) 2000-01-25
EP0966966A3 (en) 2000-02-09
NO992692D0 (no) 1999-06-03
IL130022A0 (en) 2000-02-29
US6143325A (en) 2000-11-07
HUP9901830A2 (hu) 2001-06-28
PE20000544A1 (es) 2000-06-29
JP2000007567A (ja) 2000-01-11

Similar Documents

Publication Publication Date Title
ATE321483T1 (de) Dose
NO20003640D0 (no) Ny doseringsform
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
NO992692L (no) Nefadozon doseringsform
DE69928777D1 (de) Dosierspender
NO20005913L (no) Legemiddelsammensetning
ID27415A (id) Komposisi farmaseutik
ATE341990T1 (de) Sigmidoskop
DE59911453D1 (de) Aktivkohlefilter
DE69909757D1 (de) Ethylencopolymerisationsverfahren
DE69930866D1 (de) Dosiervorrichtung
DE59912371D1 (de) Gleitschalungsfertiger
DE59901560D1 (de) Retrograder tibianagel
DE59902874D1 (de) Buchsenkontakt
ID29262A (id) Komposisi farmasi
DE69933073D1 (de) Informationsaufzeichnungsträgercassette
DE59906931D1 (de) Exzenterzahnradgetriebe
ID27201A (id) Komposisi farmasi
DE59903966D1 (de) Exzenterzahnradgetriebe
ATE262513T1 (de) Benzoylpyridazine
DE59913393D1 (de) Fadenchangierung
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59908057D1 (de) Underdruckhandhabungseinrichung
FR2782671B3 (fr) Livre

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application